Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib

Patients have responded well to the multi-targeted tyrosine kinase inhibitor (TKI) Sunitinib in the clinic. But the severe toxic side effects associated with Sunitinib limit its therapeutic index. To improve the therapeutic index of Sunitinib, a prodrug strategy was employed to modify Sunitinib. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qiang, Zhou, Changhua, Chen, Xiao, Dong, Bing, Chen, Siqi, Zhang, Ning, Liu, Yawei, Li, Anrong, Yao, Meicun, Miao, Ji, Li, Qing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626378/
https://www.ncbi.nlm.nih.gov/pubmed/26513662
http://dx.doi.org/10.1371/journal.pone.0141395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626378/
https://www.ncbi.nlm.nih.gov/pubmed/26513662
http://dx.doi.org/10.1371/journal.pone.0141395

Ejemplares similares